EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ten‐Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS‐TILDA)

Lamya Al Shuhaimi iD, Ian D Maidment, Martin C Henman, Phyo K Myint, Juliette O'Connell, Caitríona Ryan, Philip McCallion iD, Mary McCarron, Maire O'Dwyer

Journal of Intellectual Disability Research · 2025-11 · 69 (11) · 1284-1294

DOI: 10.1111/jir.70018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Intellectual Disability Research, online erschienen am 26.07.2025. Verfasst von Lamya Al Shuhaimi und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Intellectual Disability, Cholinergic Antagonists, Cognitive Dysfunction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Research Board and the Department of Health in Dublin, Ireland, Trinity College Dublin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with intellectual disability are frequently exposed to medication with anticholinergic activity. In the general population, the long‐term exposure to anticholinergics has been associated with declines in both physical and cognitive function. This study aimed to examine anticholinergic exposure longitudinally in a cohort of older adults with intellectual disability (aged 40 years or over).

Method

The study examined individuals with intellectual disability aged 40 and over, who participated at two time points (Waves 1 and 4), 10 years apart, in the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS‐TILDA). The Anticholinergic Cognitive Burden (ACB) scale was used to quantify anticholinergic exposure. Logistic regression analysis was employed to examine the adverse outcomes reported at time point 2 in relation to ACB scores at time point 1. Models were adjusted for age, gender, level of intellectual disability, residence, epilepsy and polypharmacy.

Results

The study included 487 participants who provided medication data at both time points. Anticholinergic exposure remained consistent over the studied period, with approximately 30% having no exposure, 40% having mild exposure (ACB = 1–4) and 30% having high exposure (ACB = 5+). Antipsychotic medications contributed the most to the total score at both time points (Wave 1 = 35%, Wave 4 = 37%), with other anticholinergics, antiepileptics and antidepressant medications contributing 10%–16% each. Mild and high ACB scores at time point 1 were significantly associated with a higher risk of falls (odds ratio [OR] = 1.86, 95% CI: 1.03–3.38) and mental health conditions (ACB 1–4; OR = 6.60, 95% CI: 3.69–11.77; ACB 5+, OR = 17.38, 95% CI: 8.97–33.61) and lower OR for reporting dementia/Alzheimer's disease (ACB 1–4; OR = 0.39, 95% CI: 0.15–0.97; ACB 5+; OR = 0.21, 95% CI: 0.07–0.64).

Conclusion

Older adults with intellectual disability are exposed to high anticholinergic burden at the two time points, 10 years apart. Being exposed to anticholinergics at Wave 1 is significantly associated with a higher risk of falls and reporting mental health conditions at Wave 4. A review of antipsychotic prescribing practice is urgently needed to reduce the anticholinergic exposure and its adverse outcomes among older adults with intellectual disability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intellectual DisabilityCholinergic AntagonistsCognitive DysfunctionHumansMaleFemaleLongitudinal StudiesIrelandAgedMiddle AgedAdultAged, 80 and over

Stichwörter der Autor:innen

challenging behaviourcognitive behaviourintellectual disabilitymental health

Substanzen

Cholinergic Antagonists

Autor:innen und Institutionen

  • School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.
  • Trinity Centre for Ageing and Intellectual Disability, Trinity College Dublin, Dublin, Ireland.
  • School of Life and Health Sciences, Aston University, Birmingham, UK.
  • Ageing Clinical & Experimental Research (ACER) Group, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
  • School of Social Work, Temple University, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Lamya Al Shuhaimi, Philip McCallion

Förderung

  • Health Research Board and the Department of Health in Dublin, Ireland
  • Trinity College Dublin

Zitieren

APA

Al Shuhaimi, L., Maidment, I. D., Henman, M. C., Myint, P. K., O'Connell, J., Ryan, C., McCallion, P., McCarron, M., & O'Dwyer, M. (2025). Ten‐Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS‐TILDA). Journal of Intellectual Disability Research, 69(11), 1284-1294. https://doi.org/10.1111/jir.70018

Vancouver

Al Shuhaimi L, Maidment ID, Henman MC, Myint PK, O'Connell J, Ryan C, et al. Ten‐Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS‐TILDA). Journal of Intellectual Disability Research. 2025;69(11):1284-1294. doi:10.1111/jir.70018

BibTeX
@article{AlShuhaimi2025,
  author = {Al Shuhaimi, Lamya and Maidment, Ian D and Henman, Martin C and Myint, Phyo K and O'Connell, Juliette and Ryan, Caitríona and McCallion, Philip and McCarron, Mary and O'Dwyer, Maire},
  title = {Ten‐Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS‐TILDA)},
  journal = {Journal of Intellectual Disability Research},
  year = {2025},
  volume = {69},
  number = {11},
  pages = {1284--1294},
  doi = {10.1111/jir.70018}
}
Kostenlos starten →